Published in Molecules on June 23, 2014
Collagenase IV plays an important role in regulating hair cycle by inducing VEGF, IGF-1, and TGF-β expression. Drug Des Devel Ther (2015) 0.77
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol (1999) 8.46
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 6.52
In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med (2001) 4.30
Molecular imaging in drug discovery and development. Nat Rev Drug Discov (2003) 3.44
Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem (1994) 3.37
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer (2002) 3.04
In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) (2009) 2.30
Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology (2001) 2.24
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res (2000) 2.12
Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther (2003) 2.02
Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol (2006) 1.98
CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol (1998) 1.93
The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol (2007) 1.90
Matrix metalloproteinases in human melanoma. J Invest Dermatol (2000) 1.84
Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem (2005) 1.83
Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) (2009) 1.78
Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol (2007) 1.75
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer (1996) 1.71
Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol (1998) 1.65
Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J (2004) 1.65
Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res (2010) 1.60
Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev (2008) 1.54
Developing a peptide-based near-infrared molecular probe for protease sensing. Bioconjug Chem (2004) 1.42
The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci (1998) 1.37
Profluorescent protease substrates: intramolecular dimers described by the exciton model. Proc Natl Acad Sci U S A (1996) 1.35
Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol (2008) 1.28
Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer (2007) 1.27
Proteolysis in human breast and colorectal cancer. Br J Cancer (1999) 1.27
Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal Biochem (1997) 1.26
Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer (1996) 1.25
Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer (2007) 1.24
Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. J Biol Chem (2003) 1.22
Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res (2004) 1.20
Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res (1996) 1.19
A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem (2007) 1.18
Electrostatic interactions in collagen-like triple-helical peptides. Biochemistry (1994) 1.18
Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg (2000) 1.15
Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med (2011) 1.13
The DMAP-catalyzed acetylation of alcohols--a mechanistic study (DMAP = 4-(dimethylamino)pyridine). Chemistry (2005) 1.12
A statistically derived parameterization for the collagen triple-helix. Protein Sci (2002) 1.10
Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis (1998) 1.09
Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer (2000) 1.08
Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer (1998) 1.07
Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res (2000) 1.05
Extending the applicability of carboxyfluorescein in solid-phase synthesis. Bioconjug Chem (2003) 1.02
Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res (1999) 1.01
Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol (2000) 1.00
Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix metalloproteinases. Bioconjug Chem (2008) 0.96
Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe. Bioconjug Chem (2012) 0.96
Solid-phase synthesis and stability of triple-helical peptides incorporating native collagen sequences. Biopolymers (1993) 0.90
Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol (2002) 0.89
Endoscopic, rapid near-infrared optical tomography. Opt Lett (2006) 0.82